Lin Mei
@LinMeiMD_onc
Genitourinary Oncology, Penn Medicine, Abramson Cancer Center. Interested in rare GU malignacies, cancer immunology and brain metastasis. Tweets are my own view
Was dir gefallen könnte
Finially, we see the result of HERCULES trial.
Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma. ja.ma/3XfSa8H
Appreciated all the staffs. It is a lot of effort.
The Oncology Evaluation Center helps cancer patients with complications that arise in between scheduled treatments—easing their care and their anxiety. Open 24/7, it’s a place where patients can go for help with side effects, bypassing the emergency room. spr.ly/60157OiBU
Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2
In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden ow.ly/yCUo50XgSQh
Wow. Penn Medicine is the best. Appreciate @NehaVapiwala
Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala @PennMedicine #radonc
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf5EIIgTS…
I will change again.
The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.
A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist. #BladderCancer #Oncology #Immunotherapy @MattGalsky @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit doi.org/10.1200/JCO-25…
Our study regarding the race, sex and age disparity in metastatic bladder cancer. Actually, female sex and older patients didn't show worse outcomes than the comparators. clinical-genitourinary-cancer.com/article/S1558-…
Congratulations and thanks for the effort from everybody!
There are still disparities in #bladdercancer survival across the US: we found women had faster progression on #immunotherapy, while Asian patients lived longer than Black or White patients. Thank you @LinMeiMD_onc @Ron_cology @Omelghawy @flatironhealth clinical-genitourinary-cancer.com/article/S1558-…
Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer
Congratulations Vivek! @Ron_cology @PennCancer
Vivek Narayan, MD, MS receives the 2025 Pearl and Phil Innovation Research Award for his work impacting male BRCA mutation carriers as a prostate cancer clinical investigator improving treatments for BRCA-related prostate cancer and overcoming treatment resistance. @PennCancer
One of my patient was in this trial. Amazing work from Penn. @PennCancer Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine nejm.org/doi/full/10.10…
A @PennMedicine pilot study led by Ronac Mamtani, MD (@Ron_cology), demonstrated that text message check-ins, instead of in-person visits, could save cancer patients more than 60 minutes per appointment. @HemOncToday spr.ly/60122Rwj0
Specially interested to see 1 and 2.
Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/durvalumab in upper tract disease 3) Neoadjuvant DV/PD1 in MIBC (pCR >50%?) 3) Longer OS follow up for EVP 4) Data on DDXD and new FGFR3i in pretreated patients
Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉 bit.ly/42apBgy @chadihc98 @Huntsman_GU @OncoAlert @urotoday @PCF_Science
From @asco @JCOOP_ASCO 71% of US counties either lack an oncologist (20%) or lack an open cancer trials (50%). Meanwhile trends show declining % of oncologists in rural communities. Pair this with @wsj piece on community oncs being overwhelmed by clinical advances.
Legendary
Mil gracias a todos Many thanks to all Merci beaucoup à tous Grazie mille à tutti 谢谢大家 شكرا لكم جميعا תודה לכולכם Obrigado a todos Vielen Dank euch allen Tack alla Хвала свима Gràcies a tots
Thanks for our resident @ABarsouk hard work and dedication. Appreciate @Ron_cology support for your review article. We have found women's bladder cancer still has inferior outcomes even in the modern treatment era.
Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI
Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI
Nice summary.
A summary of the ADC session at #UromigosLive24 with @apolo_andrea @shilpaonc @PGrivasMDPhD @tompowles1 & @kalasri3
United States Trends
- 1. Michigan 140K posts
- 2. Ohio State 59.6K posts
- 3. Bryce Underwood 4,088 posts
- 4. Ryan Day 8,615 posts
- 5. #GoBucks 12.5K posts
- 6. Stoops 6,037 posts
- 7. Sherrone Moore 3,367 posts
- 8. Mateer 1,374 posts
- 9. Clemson 8,727 posts
- 10. Julian Sayin 6,160 posts
- 11. #TheGame 4,652 posts
- 12. #GoBlue 9,766 posts
- 13. Fortnite 231K posts
- 14. Tim Banks N/A
- 15. Venezuela 438K posts
- 16. Demond N/A
- 17. Brutus 18.6K posts
- 18. Beamer 2,030 posts
- 19. Van Buren N/A
- 20. Kentucky 22K posts
Was dir gefallen könnte
Something went wrong.
Something went wrong.